glp-1 receptor agonist pancreatitis risk meta-analysis Agonists and Comparative effectiveness of GLP-1 receptor

2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes

I 2 = 0%), and 30-day mortality rate ( OR 0.54

However, adequate adjustment of insulin doses and close monitoring after GLP-1RA initiation may decrease this risk

Nat Commun 2024

Additionally, benefits like lowering blood pressure, improving lipid disorders, improving fatty liver disease, reducing your risk of heart disease and kidney disease, and delaying the progression of diabetes-related nephropathy, have been documented

This aligns better with clinical needs, especially given the shared pathophysiology between OSA and cardiovascular/metabolic disorders